RTRX Retrophin Inc.

13.26
+0.34  (+3%)
Previous Close 12.92
Open 12.99
Price To Book 2.31
Market Cap 569,628,397
Shares 42,958,401
Volume 416,799
Short Ratio
Av. Daily Volume 425,446
Stock charts supplied by TradingView

NewsSee all news

  1. Retrophin to Present at the Jefferies 2019 London Healthcare Conference

    SAN DIEGO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the Jefferies 2019 London Healthcare Conference in London, UK

  2. Retrophin Reports Third Quarter 2019 Financial Results

    Enrollment on-track in pivotal Phase 3 clinical trials to support registration of sparsentan for patients with FSGS and IgAN Third quarter revenues rose nine percent to $44 million SAN DIEGO, Oct.

  3. Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2019

    SAN DIEGO, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that it will present new data from the Phase 2 DUET Study examining the impact of sparsentan on quality of life in focal

  4. Retrophin Announces Appointment of Peter Heerma as Chief Commercial Officer

    SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Peter Heerma as chief commercial officer, effective immediately. In this newly created position, Mr. Heerma

  5. Retrophin to Present at the 2019 Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the 2019 Cantor Global Healthcare Conference in New York City

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Development to be discontinued - noted August 6, 2019.
CNSA-001
Phenylketonuria (PKU)
Phase 3 top-line data did not meet endpoints - August 22, 2019.
Fosmetpantotenate
Pantothenate kinase-associated neurodegeneration (PKAN)
Phase 3 top-line data due 1H 2021.
Sparsentan - DUPLEX
Focal segmental glomerulosclerosis (FSGS)
Approved Mar 18 2015
Cholbam
Rare Bile Acid Synthesis Disorders
Phase 3 data due 1H 2022.
Sparsentan
IgA nephropathy
FDA Approval announced June 28, 2019.
New formulation of Thiola (tiopronin)
Cystinuria

Latest News

  1. Retrophin to Present at the Jefferies 2019 London Healthcare Conference

    SAN DIEGO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the Jefferies 2019 London Healthcare Conference in London, UK

  2. Retrophin Reports Third Quarter 2019 Financial Results

    Enrollment on-track in pivotal Phase 3 clinical trials to support registration of sparsentan for patients with FSGS and IgAN Third quarter revenues rose nine percent to $44 million SAN DIEGO, Oct.

  3. Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2019

    SAN DIEGO, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that it will present new data from the Phase 2 DUET Study examining the impact of sparsentan on quality of life in focal

  4. Retrophin Announces Appointment of Peter Heerma as Chief Commercial Officer

    SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Peter Heerma as chief commercial officer, effective immediately. In this newly created position, Mr. Heerma

  5. Retrophin to Present at the 2019 Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the 2019 Cantor Global Healthcare Conference in New York City

  6. Retrophin Announces Topline Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN

    FORT Study did not achieve its primary or secondary endpoints Company to host conference call and webcast today at 8:30 a.m. ET SAN DIEGO, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today